Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Key Highlights
- ➤Sutro (STRO) will present pipeline updates at the October 12-15 World ADC Conference
- ➤STRO-004 early clinical safety and pharmacokinetic profile featured in a plenary presentation
- ➤STRO-006 presentation will detail PDX response and translational biomarker insights
- ➤STRO-227 preclinical characterization will assess efficacy and safety in ADC resistance models
Expert Statements
Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma
“Sutro's presence at World ADC this year reflects meaningful progress across our pipeline, from a plenary presentation on the early clinical safety and pharmacokinetic profile of STRO-004 to new preclinical insights on STRO-006 and our first wholly-owned dual-payload ADC, STRO-227.”
Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma
“Notably, we look forward to sharing how the design principles that shaped STRO-004, along with our preclinical findings, are translating into its emerging clinical profile.”
Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma
“Together, these presentations offer further evidence that our platform has the potential to deliver next-generation ADCs with a wider therapeutic index for complex targets and the ability to overcome resistance to single-payload ADCs.”
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 17th Annual World ADC Conference, taking place in San Diego, October 12-15, 2026.
“Sutro's presence at World ADC this year reflects meaningful progress across our pipeline, from a plenary presentation on the early clinical safety and pharmacokinetic profile of STRO-004 to new preclinical insights on STRO-006 and our first wholly-owned dual-payload ADC, STRO-227,” said Hans-Peter Gerber, Ph.D., Sutro's Chief Scientific Officer. “Notably, we look forward to sharing how the design principles that shaped STRO-004, along with our preclinical findings, are translating into its emerging clinical profile. Together, these presentations offer further evidence that our platform has the potential to deliver next-generation ADCs with a wider therapeutic index for complex targets and the ability to overcome resistance to single-payload ADCs.”
Get started
Create a free account to read the full story.